Business Wire

Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business

Share

In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc. (Headquarters: Massachusetts, USA; referred to hereafter as “Avecia”), a subsidiary of Nitto, and other related business establishments and group companies. This investment will significantly increase the manufacturing capacity of its oligonucleotide therapeutic business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005336/en/

Photo of the new building at the Milford facility (Graphic: Business Wire)

Photo of the new building at the Milford facility (Graphic: Business Wire)

In addition to the already existing clinical development centered around rare diseases, development of oligonucleotide therapeutics for common diseases and intractable diseases such as cancer is progressing towards commercialization.

Since the acquisition of Avecia in 2011, Nitto has continued to invest in resources in order to provide comprehensive value in raw material manufacturing, contract manufacturing of the drug substance, final formulation, contract manufacturing of drug product and analytical services. In doing so, Nitto has contributed to the growth of the oligonucleotide therapeutic market.

At Avecia headquarters in Milford MA, Avecia is expanding process and analytical development of oligonucleotide therapeutic manufacturing based on its experience in handling more than 1,200 oligonucleotide sequences to enhance its quick and reliable manufacturing process design services. Furthermore, Avecia will establish a new building and production line for commercial manufacturing of the drug substance in order to secure sufficient supply for commercial scales. The process development building is scheduled to start operations in 2021 and the commercial manufacturing building and production line are scheduled to start operations in early 2023.

Future plans include another 25 billion Japanese yen investment to further increase the supply capacity of the polymer support used for oligonucleotide therapeutic manufacturing and expand the production line of oligonucleotide therapeutics for early clinical scales.

As a manufacturer of high-performance materials, Nitto aims to realize a better society and environment through the development of new products and new functions under its brand slogan, “Innovation for Customers”. By strengthening its capacity, Nitto can seamlessly handle manufacturing from initial stages of development to commercial scales. This will allow Nitto to support the rapidly growing oligonucleotide therapeutic market and contribute to creating a safe and healthy society.

About NITTO DENKO AVECIA INC.

Nitto Denko Avecia Inc. is a leader in oligonucleotide therapeutic manufacturing and development services with facilities located in Milford (Massachusetts) and Cincinnati (Ohio). Services for DNA and RNA-based therapeutics are provided from milligram to commercial scale. For more information, please visit www.Avecia.com.

About Oligonucleotide Therapeutics

Oligonucleotide therapeutics are comprised of nucleic acids such as DNA and RNA and are considered to be the next generation of pharmaceuticals following antibody therapeutics. Due to their direct effect on gene expression, oligonucleotide therapeutics may prove to be a revolutionary medicine that enables the treatment of illnesses that were previously difficult to treat. As a result, development towards commercialization is gaining momentum.

Contact information

Takeshi Nishiwaki
E-mail: communication_group@nitto.co.jp
TEL:+81-6-7632-2101/FAX:+81-6-7632-2568
Brand Strategy Department, Nitto Denko Corporation

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A Digital Transformation: Mary Kay Inc. Launches Immersive Virtual Experience Platform Suite 13 TM15.4.2021 15:03:00 CEST | Press release

Global beauty brand Mary Kay Inc. and its Mary Kay Global Design Studio present Suite 13TM, an innovative virtual beauty experience that leverages the use of virtual reality to digitize Mary Kay's first virtual pop-up showroom. Designed with the latest virtual reality technology, the new Suite 13TM offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience where users can virtually browse the beauty brand’s portfolio of skin care as well as explore the company and its founder Mary Kay Ash’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005306/en/ The new Suite 13™ offers Mary Kay Independent Beauty Consultants and their customers a 360-degree, 3D beauty experience. (Photo: Mary Kay Inc.) The new Suite 13TM invites users to tour through virtual “rooms”. Upon entering the “Lobby”, users can learn about the Company’s global legacy. The other virtual rooms include the “P

Conviva Works With ServiceNow to Provide Next Generation Customer Service for Streaming Customers15.4.2021 15:00:00 CEST | Press release

Conviva, the intelligence cloud for streaming media, today announced that its streaming insights data will be integrated with ServiceNow telecom and media industry solutions. This new integration will enable streaming providers to offer more reliable streaming services and personalized customer care experiences to drive user acquisition, reduce operational costs and increase customer lifetime value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005156/en/ Conviva and ServiceNow Provide Next Generation Customer Service For Streaming Customers (Graphic: Business Wire) Conviva’s integration with ServiceNow extends ServiceNow’s offerings within the telecom and media industry and will help streaming customers to automate proactive case creation and ticket generation to identify and diagnose incidents across the entire video delivery supply chain. Adding this additional layer of automation to root cause analysis delivers im

Thales IoT SAFE to Secure Cloud Connectivity for New Internet of Things Services in Canada15.4.2021 15:00:00 CEST | Press release

Thales technology is at the heart of a new Canadian IoT project that is enabling instant, secure and scalable cloud connectivity for SIM/eSIM-enabled IoT. Working alongside TELUS, a leading Canadian wireless network operator, and the Canadian Internet Registration Authority (CIRA), the project’s certification partner, Thales is supplying SIMs and the IoT server, both compliant with the GSMA IoT SAFE specifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005017/en/ (Photo: Thales) The Thales IoT SAFE service offers an interoperable framework enabling swift deployment of IoT applications. Delivered in a plug & play SaaS mode, it benefits minimal integration effort. It creates a scalable and automatic environment for cloud data security of SIM-equipped devices with a remote management feature. TELUS continues its IoT expansion with devices across Canada, offering enterprises an innovative system that eliminates th

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella15.4.2021 14:03:00 CEST | Press release

Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Ascension St. John Macomb-Oakland Hospital and Dr. Amir Kaki, interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005234/en/ Impella Clinical Pathway to Class I Guideline (Graphic: Business Wire) The two-arm trial will compare the benefits of HRPCI with Impella versus HRPCI without Impella support. The primary endpoint of the study is the composite of all-cause deat

Blackstone Hires Paul Morrissey to Lead European Investing for Blackstone Growth (BXG)15.4.2021 13:30:00 CEST | Press release

Blackstone (NYSE: BX) today announced that it has hired Paul Morrissey, a seasoned investment professional with extensive private equity and venture capital experience, as a Managing Director to lead investing across Europe for Blackstone Growth (BXG). This newly created role will see Mr. Morrissey manage the European deployment for BXG, which recently completed the final close of its oversubscribed, inaugural $4.5 billion growth equity fund – the largest first-time growth equity private vehicle ever raised. BXG has already made significant investments in fast-growing European companies, including Epidemic Sound, which delivers restriction-free music to internet content creators across the globe, and oat milk pioneer, Oatly. Jon Korngold, Global Head of Blackstone Growth, said: “I’m delighted that Paul has joined us to lead BXG in Europe. Paul is a world-class growth equity investor and his appointment underlines Blackstone’s already-strong commitment to partnering with fast-growing Eu

Bank of America Reports First-Quarter 2021 Financial Results15.4.2021 12:04:00 CEST | Press release

Bank of America reported its first-quarter 2021 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005486/en/ Bank of America newsroom at https://newsroom.bankofamerica.comQ1-21 Bank of America Financial Results Press ReleaseQ1-21 Bank of America Investor Relations PresentationQ1-21 Bank of America Supplemental Information Bank of America Investor Relations website at https://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information: Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 9 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the co

REPLY: The Creative Challenge 2021, Organized by Reply, Kicks off in Search of the Creative Talents of Tomorrow15.4.2021 12:02:00 CEST | Press release

Reply announces the opening of registrations for the https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fchallenges.reply.com%2Ftamtamy%2Fchallenges%2Fcategory%2Fcreative&esheet=52411638&newsitemid=20210415005479&lan=en-US&anchor=Creative+Challenge+2021&index=1&md5=a7a453e02454ad9f83092e3da17a94e4 Creative Challenge2021, the team-based competition and part of the Reply Challenges program, that brings together students and young creatives from all over the world. The challenge consists of the development of a creative concept, conceived by some of Europe’s most qualified art directors and marketing and communication professionals. In last year's edition, over 6,200 participants between 18 and 29 years old from more than 70 countries answered the call and, split into over 1,000 teams, submitted more than 500 projects. The challenge, which is going to take place online from Friday 21st to Sunday 23rd May, is enriched by the participation of world-renowned partners such as AC

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom